drugset / Trial / NCT01995331
Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Severe aplastic anemia (SAA)is characterized by the depletion of hematopoietic precursors associated with life-threatening complications. High-dose cyclophosphamide has been found to yield a complete response (CR) in adults and children with SAA.However, the optimal dosage of cyclophosphamide for patients in childhood remains unclear. So we explore the ideal dosage of cyclophosphamide for the treatment of children with SAA.
Timeline
- Start
- 2012-03
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 30 mg/kg | Intravenous |
| Background | Cyclosporine | Peptide | 5 mg/kg | Oral |
| Background | Cyclosporine | Peptide | 12 mg/kg | Oral |
| Background | human granulocyte colony-stimulating factor | Protein / enzyme biologic | 5 ug/kg | Subcutaneous |